BeyondSpring Inc.

BYSI · Nasdaq · SIC 2834: Pharmaceutical Preparations
117
SEC Filings

Business Summary

BeyondSpring Inc. (BYSI) is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. The company's pipeline includes plinabulin, a novel anticancer agent being developed for multiple oncology indications. BeyondSpring conducts clinical trials and research aimed at bringing new treatments to patients with unmet medical needs in oncology.

Next Earnings

Q2 FY2026 — expected 2026-09-13

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionBYSIdiscussed_in_filing Cybersecurity
topic_mentionBYSIdiscussed_in_filing Trusted Computing
topic_mentionBYSIdiscussed_in_filing Blockchain & Crypto
topic_mentionBYSIdiscussed_in_filing Capital Expenditure
topic_mentionBYSIdiscussed_in_filing Regulation
topic_mentionBYSIdiscussed_in_filing Healthcare & Bio
topic_mentionBYSIdiscussed_in_filing Platform & Ecosystem
topic_mentionBYSIdiscussed_in_filing Sovereign & Government
topic_mentionBYSIdiscussed_in_filing Cybersecurity
topic_mentionBYSIdiscussed_in_filing Trusted Computing
topic_mentionBYSIdiscussed_in_filing Blockchain & Crypto
topic_mentionBYSIdiscussed_in_filing Capital Expenditure
topic_mentionBYSIdiscussed_in_filing Regulation
topic_mentionBYSIdiscussed_in_filing Healthcare & Bio
topic_mentionBYSIdiscussed_in_filing Platform & Ecosystem
topic_mentionBYSIdiscussed_in_filing Sovereign & Government
topic_mentionBYSIdiscussed_in_filing Cybersecurity
topic_mentionBYSIdiscussed_in_filing Trusted Computing
topic_mentionBYSIdiscussed_in_filing Blockchain & Crypto
topic_mentionBYSIdiscussed_in_filing Capital Expenditure

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-252025-12-310001171843-26-001908EDGAR136K words
2025-03-272024-12-310001171843-25-001758EDGAR

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001171843-25-007236EDGAR28K words
2025-08-132025-06-300001171843-25-005376EDGAR
2025-05-122025-03-310001171843-25-003088EDGAR

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-250001171843-26-001890EDGAR3K words
2025-12-150001171843-25-007943EDGAR
2025-11-210001171843-25-007497EDGAR
2025-11-120001171843-25-007217EDGAR
2025-09-230001171843-25-006027EDGAR
2025-09-160001171843-25-005922EDGAR
2025-08-130001171843-25-005355EDGAR
2025-07-030001171843-25-004306EDGAR
2025-05-120001171843-25-003087EDGAR
2025-04-110001171843-25-002158EDGAR

117 total filings indexed. 102 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

oncology biopharmaceuticals

Company Identity

CIK0001677940
TickerBYSI
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 8a688887527898bd020e1799d88666047989aadc96c8f6c1588933e7d41b916e
parent: 003bcaef38e1378d0f065f68f43d94d9ec9b22c2bc59f7b3a341bbc972cd0eb7
content hash: 758c74bb781b778853d2ae6e71141750a57e0d505834593d3731f31b178a89cb
signed: 2026-04-13T04:44:09.980Z
sources: 5 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf